

REVIEW

Skin and soft tissue diseases and their treatment in society

Priya Sen¹, Preeti Khulbe¹, Eknath D Ahire², Manish Gupta¹, Nidhi Chauhan¹, Raj K Keservani^{3*}

¹Gyan Vihar School of pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur 302017, Rajasthan, India

²Department of Pharmaceutics, MET's, Institute of Pharmacy, Bhujbal Knowledge City, Adgaon, Nashik 422003, Maharashtra, India

³Faculty of B. Pharmacy, CSM Group of Institutions, Prayagraj 212111, Uttar Pradesh, India

ABSTRACT

Infections of the skin and the soft tissues (SSTIs) beneath it are caused by microorganisms. Variation exists among them in terms of causes, symptoms, and intensity. Impetigo is usually caused by *staphylococci*. When you touch impetigo sores or their clothing, bed linen, towels, or toys, you risk contracting impetigo. When assessing patients with soft tissue complaints, it is important to take into account viral pathogenesis, especially in immunocompromised patients. It may be difficult to accurately categorise some soft-tissue pathogenic microorganisms. Among the tissues that could be impacted are the skin, skeletal muscle, fascia, and subcutaneous tissue. Impetigo is characterized by mouth and nasal sores. The wounds bleed freely, leak pus for a few days, and crust with honey. Open sores can spread *via* garments and towels. Itching and soreness are usually mild. Bullous impetigo develops larger blisters on newborns, babies, and children under five. Ecthyma is a severe form of impetigo that causes pus-filled lesions. When an illness is mild to moderate, antibiotics taken orally will do the trick, but when it's severe but not complicated, antibiotics given intravenously will be required. Awareness of the potential for resistant bacteria to produce SSTIs can aid in the selection of the appropriate antibiotic therapy.

Key words: skin, soft tissue diseases, treatment, tissue infections, microorganisms

INTRODUCTION

Skin and soft tissue infections (SSTIs) include a wide range of illnesses, make up a sizable portion of infections that necessitate hospitalisation, and are linked to significant morbidity.^[1,2] SSTIs, which can range in severity from moderate infections like impetigo contagiosa. Or ecthyma to severe, life-threatening infections like suppurative fasciitis, entail microbial penetration of the skin's superficial layers and beneath soft tissues.^[3,4] The outermost layer in the human body, the skin serves a variety of purposes including thermoregulation, minimising liquid and salt loss, and

shielding the body from microorganisms including viruses, germs, allergens, and hazardous chemicals.^[5]


Skin has three layers. The epidermis gives our skin its pigmentation it serves as an impenetrable barrier. Calcified tissue, hair follicles, and sweat glands are all situated under the epidermis layer. The hypodermis skin layer is made up of fat and connective tissues. Melanocytes, are present in the epidermal layer, are responsible for skin colour and produce the pigment melanin.^[6]

The thickness of each skin layer varies by body location based on the epidermal and dermal layers. Palms and soles have the thickest hairless skin because the epidermis has an additional layer, the stratum lucidum. Upper back is thickest based on dermis thickness, but histologically it is "thin skin" because the epidermal thickness lacks the stratum lucidum layer and is thinner than hairless skin.

*Corresponding Author:

Raj K Keservani, E-mail: rajksops@gmail.com; <https://orcid.org/0000-0003-2604-7440>

Received: 22 September 2022; Revised: 19 October 2022; Accepted: 1 February 2023; Published: 30 May 2023
<https://doi.org/10.54844/cai.2022.0150>

 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which allows others to copy and redistribute the material in any medium or format non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Skin layers

The epidermis has stratum basale, stratum spinosum, stratum granulosum, stratum lucidum, and stratum corneum (the most superficial portion of the epidermis).

Stratum basale is the lowest layer, separated from the dermis by the foundation membrane (basal lamina) and linked to it by hemi desmosomes. Cuboidal to columnar mitotically active stem cells produce keratinocytes in this stratum. Stratum spinosum, 8–10 cell layers, contains irregular, polyhedral cells with cytoplasmic extensions, commonly called “spines” that extend outward and contact neighbouring cells by desmosomes. These cells are dendritic. Stratum granulosum has 3–5 cell layers with diamond-shaped cells and keratohyalin granules. Keratohyalin granules contain keratin precursors that bundle and agglomerate. The lamellar granules contain glycolipids that are released to the cell surface and act as glue, keeping the cells together. Stratum lucidum, 2–3 cell layers, is present in thicker skin on the palms and soles. It consists of eleidin, a transformation product of Keratohyalin. The stratum corneum has 20–30 layers of keratin and horny scales comprised of dead keratinocytes, called enucleate squamous cells. This is the thickest layer, especially in callused skin. Dead keratinocytes in this stratum secrete defending, our first immunological defence.^[6]

Diagnoses, disease seriousness, and antimicrobial resistance histories are three modern issues that complicate the medical assessment of individuals with SSTs. Numerous germs are capable of causing soft-tissue infections, and while some microorganisms could be responsible for a specific kind of disease, clinical manifestations of these illnesses frequently overlap. The topic of diagnostic hints or algorithmic methods is explored. The Infectious Diseases Association of America-US Public Health Service Grading System for evaluating suggestions in treatment protocols is used to represent the intensity of and data for every particular prescription for treatment.^[7]

Different types of skin and soft tissues diseases are impetigo, cutaneous abscesses, cellulitis and erysipelas and necrotizing skin and soft-tissue infection.

IMPETIGO

Impetigo is a widespread skin condition that is characterised by distinct pus filled blisters and is almost invariably brought on by *b-hemolytic staphylococci* and/or *Staphylococcus aureus* (*S. aureus*). Impetigo is more common in extremely impoverished youngsters in tropical or subtropical climates during the summertime, but it is as widespread in northern climes. Although elder adolescents and adults may sometimes be affected, children ages two-five have the highest frequency of the condition. All species are vulnerable, while there is no gender preference. An infection of the skin that is widespread worldwide.^[8,9] Impetigo often develops on uncovered parts of the body, namely the face and limbs. Although commonly many and with either a blister or

non-blister appearance, the wounds are nonetheless highly confined. Blister lesions start out as superficial vesicles that quickly grow into flaccid bullae filled with clear yellow fluid. Over time, this fluid darkens, gets more turbid, and occasionally becomes purulent. Bullae can rupture and frequently leave behind a thin, lacquer-like dark coating.^[10]

Etiology

Bacteria, specifically *staphylococci* species, are almost always to blame for impetigo. When you come into contact with the sores of someone who is infected with impetigo or with goods that they have touched, such as clothing, bed linen, towels, and even toys, you run the risk of becoming exposed to the germs that cause impetigo.^[11]

Clinical manifestations

The sores that are typically found around the mouth and nose are the most prominent sign of impetigo. The wounds bleed easily, discharge pus for a few days, and eventually crust over with a honey-colored substance. It's possible for open wounds to spread to other parts of the body through contact with things like clothing and towels. In most cases, itching and pain are not severe. A less common variant of impetigo known as bullous impetigo causes bigger blisters on the trunk of newborns, babies, and children under the age of five. Ecthyma is a severe form of impetigo that can result in excruciatingly painful sores that are filled with pus or fluid.^[11]

Diagnosis

If your doctor suspects you have impetigo, he or she will likely search for sores on your body or face. In most cases, laboratory testing is not required. In the event that the sores do not heal despite receiving antibiotic treatment, your physician may take a sample of the liquid that is produced by a sore and test it to determine which types of antibiotics would be most effective on the sores.^[11]

Treatment

Applying prescription mupirocin antibiotic ointment or cream to the sores two to three times per day for five to ten days is the recommended treatment for impetigo. Apply a damp compress for a few minutes or soak the area in warm water before applying the medication (Table 1).^[11] Table 1 comprising the different medication on the impetigo disease condition.

Table 1: Different medication for the impetigo disease condition

No.	Name of the medication	Dose
1	Dicloxacillin	In adults-2.50 g quarter in die In children-0.12 g in four divided doses
2	Cephalexin	In adults-2.50 g quarter in die In children-0.25 g in four divided doses
3	Erythromycin	In adults-2.50 g quarter in die In children-0.40 g in four divided doses

ABSCESSSES, CELLULITIS, AND ERYSIPELAS

Cutaneous abscesses

Pus-filled areas in the depth skin layer and dermis are known as cutaneous abscesses. They are typically hurtful, soft, fluctuating red nodules that are frequently topped by pustules and ringed by erythematous inflammation. Cutaneous abscesses are frequently due to bacterial in nature, harbouring both local skin-specific bacteria as well as microorganisms from nearby mucosal surfaces. Only around 25% of all cutaneous abscesses include *S. aureus*, which is often found as an exposure to infectious.^[12] To effectively treat abscesses and inflammatory epidermoid cysts, a cut must be made, the pus must be thoroughly removed, and the cavity must be probed to dislodge loculations. While some medical professionals compress the insertion site with gauze or stitch it shut, dressing the insertion site with a sterile bandage is typically the simplest and most successful way to manage the wound. It is seldom essential to use gramme stain, cultivation, and topical antibiotics. Numerous sores, epidermal ulceration, highly compromised host defences, widespread surround cellulitis, or systemic inflammatory symptoms of inflammation, such as high fever, are unusual cases.^[13,14]

Etiology

If you have a tiny skin lesion, such as a small cut or graze, or if a sebaceous gland (oil gland) or sweat gland in your skin becomes blocked, bacteria can enter into your skin and produce an abscess. This can also happen if you have a skin infection.^[13,14]

Clinical manifestation

A round bump hidden beneath the surface of your skin. Ache and discomfort in the region that was impacted. Redness and warmth in the area that's been damaged. An accumulation of pus, either white or yellow, that is clearly visible under the skin in the affected area.^[13,14]

Diagnosis and treatment

After you have scheduled a consultation with your primary care physician, he or she will look over your past medical records and carry out a physical examination in order to visually evaluate the abscess. Your doctor will be able to determine if the abscess was caused by an injury or an ingrown hair the best by performing a thorough physical examination on you. In addition, they will most likely inquire about any accompanying symptoms, such as whether or not you have a temperature.

It is imperative that you discuss the possibility of having an abscess with your primary care physician, even if you are unsure whether or not you actually have one. If left untreated, an abscess can result in a

number of significant consequences and even become life threatening.

The location of cysts and abscesses on the body affects how they are treated. Some cysts might not even need to be treated. Others that are hurting or uncomfortable may need to be taken out. Abscesses are typically excruciating illnesses that need to be treated to stop the infection from spreading to other areas of the body and to ease the pain. Internal organ cysts and abscesses may not be visible or able to be felt. Careful examination and diagnosis are necessary. To detect an illness, blood tests may be helpful. Doctors may use imaging methods including X-rays, CT scans, and MRI scans to pinpoint the cyst or abscess's location.^[13,14]

A variety of over-the-counter antibiotic ointments are fast-acting and relaxing, so you can't go wrong with them. You might not even need to look very far to find a tube of Neosporin because many individuals keep one in their medication cabinet. Additionally, it might prevent the infection from spreading.^[12,13]

CELLULITIS AND ERYSIPELAS

Diseases linked with deeper bullous foci, such as epidermal abscess, necrotizing enterocolitis, septic arthritis, and osteomyelitis, are not included in this definition of widespread, widespread skin problems. The terms "cellulitis" and "erysipelas" are unfortunately inconsistently used by doctors. For those, the difference between the 2 names is related to the depth of the infection: cellulite impacts the deepest dermal as well as fat tissue, whereas epithelialization affects the top epidermis, including the superficial lymphatics. The sores are elevated beyond the surface of the epidermis, and there is a distinct boundary between the affected and unengaged tissue, which clinically distinguishes erysipelas from other types of cutaneous disease.^[15] This condition is much more frequent in newborns, small kids, and elderly persons. Although identical sores can be brought on by *streptococci* from serogroups C or G, *b-hemolytic streptococci* (often group A) are virtually always to blame.^[16]

Etiology

While cellulitis is often brought on by staphylococcus bacteria, erysipelas is frequently brought on by streptococcus bacteria. Cellulitis and erysipelas can both be brought on by either sort of bacteria, though.^[17]

Clinical manifestation

Erysipelas is a type of cellulitis, which shows up as an area of erythema, edoema, and warmth on the skin. Cellulitis results from bacterial penetration through breaks in the skin barrier. The dermis or subcutaneous

region contains pus when there is an abscess on the skin.^[17]

Diagnosis and treatment

In most cases, a diagnosis of cellulitis or erysipelas can be made solely based on the patient's medical history and the results of a physical examination. However, blood cultures and microscopic examination of cutaneous aspirates, biopsies, or swabs should be considered for certain patients, including immunocompromised individuals.

Antibiotics are typically prescribed for patients suffering from erysipelas or cellulitis. The drug is administered through a drip that is placed straight into a vein. Tablets are sufficient treatment for instances that are less severe. People who require medical attention at a hospital are typically required to remain there for around one week.

Cellulitis can be treated with a variety of topical medicines, such as Silvadene, Bacitracin, and Neosporin, which assist to calm the burning and inflammation of the affected tissue and promote the body's natural healing process.^[17]

NECROTIZING SKIN AND SOFT-TISSUE INFECTIONS

The clinical features, accompanying systemic signs, and therapeutic approaches of necrotizing skin and soft tissue infections are distinct from those of the lighter, bacterial overgrowth.^[17] They frequently have terrible depth. These are destructive because they induce significant tissue damage and can have deadly consequences; they are severe because they might affect the deep tissue and/or muscular sections. These illnesses are typically "secondary" infections because they arise after a first skin rupture brought on by trauma or surgery. They can be pathogens or monomicrobial (often involving *streptococci* or, rarely, *staphylococci*), (involving a mixed aerobe-anaerobe bacterial flora).

Necrotizing fasciitis

A very uncommon underlying infection called necrotizing fasciitis spreads along deep tissue planes and goes beyond the more visible symptoms of infection, such as inflammation, redness and other skin abnormalities.^[18] Fasciitis can occasionally provide the false impression that the aponeurosis or muscle fascia are implicated. The fascia that is most frequently mentioned is called the superficial fascia, and it is made up of all the tissue that lies between the skin and the underneath muscles (*i.e.*, subcutaneous tissue).^[19] In 80% of total of instances, an extension from a skin infection is visible. In many cases, the first lesion is insignificant, such as a small abrasion, bug bite, injection site (in the case of drug users), or

boil. Rare incidences of contamination across the fascial planes of the perineum, thigh, groin, and abdomen have occurred in Bartholin gland abscess or perianal abscess. Only 20% of individuals have skin lesions that are noticeable.

Etiology

There are several different kinds of bacteria that have the potential to produce necrotizing fasciitis, also known as the "flesh-eating sickness". Experts in the field of public health believe that the most common cause of necrotizing fasciitis is group A *Streptococcus*, sometimes known as group A strep.^[18]

Clinical manifestation

Bacteria are able to penetrate the body through any openings in the skin. A few nicks and scratches, bruises, bites and stings from insects, wounds caused by needle sticks (including those caused by the use of intravenous drugs), wounds caused by surgery.^[18]

Diagnosis and treatment

Doctors can identify necrotizing fasciitis in addition to examining the wound or infection by: performing a biopsy (taking a tissue sample). Analyzing bloodwork to look for infection and muscle injury indicators. Viewing the injured area's imaging (CT scan, MRI, and ultrasound).

Early, forceful surgical investigation and debridement of necrotic tissue are the mainstays of treatment for necrotizing fasciitis. In conjunction with surgery, a broad-spectrum parenteral antibiotic regimen is prescribed. Usually, substantial incisions that extend beyond the suspected area of involvement are required during the initial examination.^[18]

The initial treatment consists of a combination of ampicillin, ampicillin-sulbactam, and either metronidazole or clindamycin. Metronidazole, clindamycin, or carbapenems (imipenem) are all effective antimicrobials; anaerobic coverage is quite critical for type 1 infections (Table 2).^[18,19] Table 2 comprising the various medication on the Necrotizing Fasciitis disease condition.

Anaerobic streptococcal myositis

Anaerobic streptococci cause a more indolent infection than other *streptococci*. Unlike other necrotizing infections,

Table 2: Medications for the Necrotizing Fasciitis disease condition

No.	Name of the medication	Dose
1	Meropenem	In adults-1000 mg in every 6–8 h intravenous
2	Oxacillin	In adults-1000–2000 mg in every 4 h intravenous

infection of the muscle and fascial planes by *anaerobic streptococci* usually is associated with trauma or a surgical procedure. Incision and drainage are critical. Necrotic tissue and debris are resected but the inflamed, viable muscle should not be removed, because it can heal and regain function. The incision should be packed with moist dressings. Antibiotic treatment is highly effective. These organisms are all susceptible to penicillin or ampicillin, which should be administered in high doses.^[20]

Etiology

Acute interstitial myositis caused by anaerobic streptococcal myonecrosis resembles subacute clostridial gas gangrene in terms of clinical presentation. Three to four days after an accident, edoema and a large amount of seropurulent exudate are the first symptoms to appear. In contrast to the early onset of pain in gas gangrene, discomfort manifests later.^[21]

Clinical manifestation

The clinical presentation of anaerobic streptococcal myonecrosis is quite similar to that of subacute clostridial gas gangrene. This condition is classified as an acute interstitial myositis. The first symptoms, which can appear anywhere from three to four days after an injury, are swelling and a profuse discharge of purulent material. Pain doesn't start until much later, in contrast to how quickly it manifests itself in gas gangrene.^[21]

Diagnosis and treatment

A thorough physical examination, blood tests, electromyography (a neurological test that evaluates the electrical activity in your muscles), and a muscle biopsy, which entails taking a tiny sample of muscle tissue for testing, are all required for the diagnosis of myositis.

The majority of myositis patients benefit from a mix of immunosuppressive and steroid medication together with carefully monitored activity. Numerous years of very low doses of steroids and immune system suppressants are frequently required. This may raise the chance of contracting an infection.^[22]

ANIMAL BITES

In 80% of cases, a skin lesion extends beyond it. Although dogs and cats are responsible for the majority of bites, wild animals and exotic pets can also bite people. Thankfully, 80% of the injuries are mild, but the other 20% will result in 10 thousand annual inpatient stays and 1% of all visits to emergency departments. The normal oral microbiota of the bitten animal, human tissue microorganisms, and sporadic secondary invaders are the main pathogens in these wounds (*e.g.*,

S. aureus and *S. pyogenes*).^[21]

Patients that arrive 8 h after an accident ask for cellular pertussis vaccine or wound treatment, and some are worried about rabies. People who seek medical help 8–12 h after an accident often have an infection that has taken hold. After animal attacks, the fastidious gram-negative rod *Capnocytophaga canimorsus*, formerly known as DF-2, can induce bacteremia and deadly sepsis, especially in those with asplenia or preexisting liver illness. Gram-negative rods that are facultative are rare. Typical anaerobic bacteria identified from animal bites wounds include bacteroides species, *peptostreptococci* etc. While cat attack injuries have much less crushing damage and tissue trauma than do dog bite injuries, they are frequently more serious and have a greater portion of osteomyelitis and septic arthritis. Empirical therapy of dog and cat bites is similar.^[22] Anaerobic bacteria (65% vs. 50%) and *P. multocida* (75% of total vs. 50% of total) are more common in both cat and dog scratch. Amoxicillin-clavulanate has been investigated in a short series for oral, outpatient treatment,^[23] and is suggested (B-II). Doxycycline and other antibiotic are a few different oral medications 1st generation cephalosporins should be avoided because they have ineffective *in vitro* action against *P. multocida*. Examples include cephalexin, clindamycin (D-III) etc. (Table 3).^[23]

HUMAN BITE

Human bite wounds are typically more severe than animal bite wounds and frequently arise from aggressive behaviour. Both occlusive injuries—where the lower teeth attack the body part—and clenched-fist injuries—where the teeth of one individual are struck by the teeth of another—are types of wounds. 10% to 20% of occlusive wounds happen during sexual encounters. Children's bite injuries may be due to sports-related activities (check for embedded teeth), but the doctor should be made aware of any potential child abuse. Staphylococci, etc. are most common oxidative pathogens, while *streptococci*, particularly *viridans* streptococci, are present in 80% of injuries, reflecting the typical oral flora of the bite mark (Table 3).^[24] Table 3 consist of the different medication on the human bite condition.

Some gram-negative rods are uncommon. In 160% of instances, anaerobes are present, however they are typically in mixed cultures. These anaerobes include *Fusobacterium nucleatum* etc. species. Sometimes is *Bacteroides fragilis* detected. As a result of the b-lactamases that many anaerobes manufacture, they are resistant to both penicillin and first-generation cephalosporins. Additionally, a human bite has the potential to spread a number of viral conditions, including herpes, hepatitis B and HIV infection.^[25–29]

Table 3. Medication for human and animal bite

No.	Name of the medication	Dose
1	Penicillin	In adults-5 g quarter in die
2	Cephalexin	In adults-5 g quarter in die
3	Cefuroxime	In adults-5 g bis in die

SOFT-TISSUE INFECTIONS FOLLOWING ANIMAL CONTACT

Anthrax

A cutaneous lesion is one of the anthrax's many clinical symptoms. Pruritus appears at the site of entrance after such an incubation time of 24–288 h, characterized by a papule, and then a painless lesion with a black scab. After 1–2 week, this eschar usually splits and sloughs. Lesion-related swelling can range from mild to severe (*i.e.*, malignant edema). Headaches, a mild to high fever, and malaise are frequently present symptoms. The techniques used to acquire samples for culturing differ on the kind of lesion. Vesicles require the blister to be opened up and two dry swabs to be dipped in the fluid. Later on, spin 2 moist swabs at the base of the ulcer or at the eschar's border. Although the ideal treatment period is unknown, 60 to 216 h seem to be sufficient. When disease is linked to bioterrorism, 2 mo of therapy are advised since concurrent inhalation may have taken place. Given the likelihood of genetically changed *B. anthracis*, ciprofloxacin is a sensible empirical treatment (B-III) till outcomes of susceptibility tests are known. It's also conceivable that other fluoroquinolones, will work. The seriousness of the sickness, particularly the level of edoema, determines whether intravenous treatment or oral medicine should be started first.^[30–32]

Etiology

Anthrax is a bacterial disease that is caused by *Bacillus anthracis*, a Gram-positive, rod-shaped bacterium. *Bacillus anthracis* is the sole obligatory pathogen in the broad genus *Bacillus*, which contains many other types of bacteria.^[31]

Clinical manifestation

High temperature and chills. A cluster of itchy blisters or bumps that form at the site where the medication was injected. A non-infected skin ulcer that has a dark centre and arises after blisters or lumps on the skin. Inflammation surrounding the wound.^[32]

Diagnosis and treatment

If inhalation anthrax is suspected, chest X-rays or CT scans can establish whether or not the patient has mediastinal widening or pleural effusion. These are X-ray characteristics that are frequently found in people who have contracted inhalation anthrax. Before the patient may start taking antibiotics for treatment, samples need to be collected from them.^[33]

Erysipeloid

The gram-positive, thin, poorly differentiated, nonspore-forming rod *E. Skin disease erysipeloid* is brought on by *rhusiopathiae*. It is a zoonotic disease that affects those who work with fishes, aquatic life, pigs, or chicken. A red papules lesion appears between 24 to 168 h after exposure, typically on the hands or fingers. When there is centre clearing, erythema spreads centrifugally. The lesions may take on the look of a target when a blue ring with a red halo around it appears. In around 1/3rd of incidents, local lymphangitis and/or lymphadenopathy occur. Penicillin (0.5 g taken orally quater in die) or amoxicillin (0.5 g taken orally ter in die) for seven to ten days looks reasonable for treating epidermal infections. Treatment with cephalosporins *etc.* should be successful for individuals who are resistant to penicillins. *E. Vancomycin, daptomycin etc.* are ineffective against *rhusiopathiae*.^[33,34]

Etiology

Erysipelothrix rhusiopathiae is the name given to the bacteria that are responsible for erysipeloid. Shellfish, fish, birds, and mammals are all potential hosts for this particular strain of bacterium. Erysipeloid is typically found in persons who work in close proximity to these animals (such as farmers, butchers, cooks, grocers, fishermen, or veterinarians).^[33]

Clinical manifestation

Lesions of the skin can sometimes appear as a cluster of erythematous papules that are follicular. Endocarditis is the manifestation of systemic erysipeloid that is seen most frequently; yet, it is still quite uncommon. It has been reported that patients have suffered from hepatic failure, renal failure, cerebral infarcts, osseous necrosis, meningitis, encephalitis, and arthritis.^[34]

Diagnosis and treatment

A skin biopsy and culture are both required to establish the diagnosis. The skin biopsy will show that Gram-positive organisms are present. Penicillin taken orally for a period of seven days is the therapy of choice for cutaneous infections that are localised; individuals who are allergic to penicillin may be treated with ciprofloxacin or a combination of erythromycin and rifampin.^[35]

Glanders

Glanders is mostly a soliped illness that is brought on by the aerobic gram-negative rod *Burkholderia mallei* (*e.g.*, horses and mules). Through skin exposure or exhalation, persons might unintentionally become hosts. Pustular skin lesions and lymphadenopathy with suppurative nodes can be significant features, even though other organs may be implicated. Most glanders infections occurred before the invention of antibiotics.

Ceftazidime, ciprofloxacin *etc.*, should all be effective, according to the outcomes of *in vitro* susceptibility studies. A recent laboratory-acquired patient was effectively treated with azithromycin and doxycycline for a further 24 weeks after imipenem and doxycycline for 14 days.^[35]

Etiology

Burkholderia mallei, a kind of bacteria, is the causative agent of the infectious disease known as glanders. Although it is possible for humans to contract glanders, the condition is more commonly found in horses. It is also contagious to donkeys and mules, and it is possible for goats, dogs, and cats, among other species, to spontaneously get the disease.^[36]

Clinical manifestation

Symptoms of glanders often include a fever accompanied by chills and sweating, aches and pains in the muscles, chest pain, tightness in the muscles, and headaches. Other symptoms may include an excessive amount of tear production in the eyes, sensitivity to light, ulcers, and diarrhoea (loose stools or poop). One to five days after infection, symptoms may begin to appear.^[36]

Diagnosis and treatment

Because instances of glanders in people are extremely uncommon, there is a paucity of data regarding antibiotic therapy of glanders in humans. Both human patients and experimental animals have shown positive responses to treatment with sulfadiazine. Tetracyclines are typically effective against glanders since the bacterium that produces them is susceptible to them.^[36]

SURGICAL SITE INFECTIONS (SSIS)

The most frequent adverse outcomes affecting hospitalised patients who have had surgery are diseases of surgical injuries.^[36] Organ/space SSIs, superficial incisional SSIs, and deep incisional SSIs are the 3 types into which SSIs fall. Within 4 weeks of the index procedure, only the superficial area between the skin and underlying muscle fascia is affected by superficial incisional SSIs, which are verified by at least one of the following symptoms: (1) Incisional leakage with pus; (2) Favourable outcomes from the growth of tissue or fluid removed aseptically from the open injury; (3) If the operator has opened the wound and there are localised indications and symptoms of discomfort or soreness, edoema, or erythema; (4) The accompanying operator or doctor's diagnostic of SSI.

The same symptoms as a superficially incisional SSI are present in a deeper post-operative infection, which affects the deep layers of skin (such as fascia and muscle) in the wound and develops within 4 weeks following the procedure or within 365 days if a

prosthetic was implanted.^[37]

INFECTIONS IN THE IMMUNE COMPROMISED HOST

Immunosuppressed people are, by definition, more prone to infection and less able to manage local illness.^[38–40] Skin and soft tissue infections are widespread, and since they can be brought on by a variety of microbes and typically occur as a result of an infections that has spread widely, they frequently present challenging health situations.^[41,42] It's crucial to take measures to safeguard the skin from needless damage, ulceration, and changes to the usual microbial flora when treating immunosuppressed individuals. No issue how little or unassuming they may look, wounds should always be thoroughly examined, and the doctor must keep in mind that the reduced inflammation frequently changes the wounds physical appearance. Thus, a methodical action to diagnosis and therapy must be added to the initial clinical evaluation.^[43,44]

Trichosporon beigelii

Trichosporon Beigelii is a rare but deadly widespread fungal illness that typically affects the skin.^[45] Examination of tissue biopsies samples reveals a combination of genuine hyphae, pseudohyphae, budding yeast, and arthroconidia that are readily misinterpreted for *Candida* species. Dermatologic signs range from many erythema blisters to maculopapular infections.^[46]

Species of *Aspergillus*, 2% to 10% of individuals with deep and protracted neutropenia get diseases that are caused by *Aspergillus* species, and their prevalence may be expanding. For each of these illnesses, death is still very severe. The most frequently recovered species is *Aspergillus fumigatus*, which accounts for 50% of cases. Other common isolates include *Aspergillus flavus*, *Aspergillus Niger*, and *Aspergillus terreus*. Rarely are *Aspergillus* species isolated from blood cultures, but autopsies frequently show that they have spread to the brain, GIT, and other visceral organs. Epidermal infections are uncommon, however they can develop as a result of hematogenous spread, locally at the sites of IV catheterisation, or at the nail plate and cuticle joints on fingers and toes.^[47] Due to their tendency for angioinvasion, aspergillus organisms can create itchy skin patches that can quickly turn necrotic and mimic pyoderma gangrenous infections.

Etiology

In immunocompromised patients, an infection caused by *Trichosporon beigelii* can spread throughout the body. The vascular invasion caused by the fungus and the subsequent hematogenous dissemination lead to the development of parenchymal lesions in cases of disseminated trichosporonosis.

Clinical manifestation

Erythematous papules on the trunk and limbs, which can sometimes develop into bullae, are one of the cutaneous symptoms of disseminated trichosporonosis. Headache, nausea, vomiting, and fever are the most common symptoms seen in patients who have an infection that affects the central nervous system.

Diagnosis and treatment

Azole medications are the first-line treatment for Trichosporon infections. Azole medications can be applied topically (with ketoconazole) to treat superficial infections, or they can be taken orally or parenterally (with voriconazole) to treat disseminated infections. *In vitro* studies have shown that voriconazole, isavuconazole, and posaconazole are highly effective against Trichosporon.^[46]

FUTURE PROSPECTS

In addition, data on their use in particular groups, such as diabetic foot infections, is insufficient. Because oxazolidinones limit bacterial toxin synthesis, they are favoured for necrotizing fasciitis. Ceftaroline may reduce *C. diff* risk. Emerging results suggest combining new and older antibiotics for synergistic efficacy and cost-effectiveness. Methicillin-resistant *Staphylococcus aureus* (MRSA) bacteraemia has been shortened by vancomycin and beta-lactam combos. Larger sample size, double-blind, appropriately powered future trials with clinically relevant end outcomes for novel antibiotics and antibiotic combinations for cSSTIs are needed to help physicians make decisions. Real-world evidence would add to safety, efficacy, and cost-effectiveness of these cSSTI therapies. A wise clinical decision on the most appropriate pharmacological agent(s) would be based on efficacy, safety profile, acceptability, cost-effectiveness, accessibility, and practicability.^[46,47]

SUMMARY

Parasites are excellent at treating mild to moderate soft-tissue illnesses. Soft-tissue infection patients with symptoms of systemic toxicity, such as a fast heart rate, low blood pressure, high or low temperature, and tachycardia. Impetigo, anthrax, animal bites, surgical wounds, and other soft skin diseases are discussed. MRSA and *S. pyogenes* are an issue. Infection-causing MRSA bacterium. MRSA infects hospitalized patients. Hospitals, assisted living, nursing homes, or home. MRSA can't be treated with *S. aureus* penicillins. Penicillin won't benefit the patient because it doesn't kill microorganisms. Sepsis treatment involves antibiotics. MRSA people can survive sepsis if they receive the proper medication quickly. Both species cause many skin and soft-tissue illnesses, thus empirical antimicrobials must be effective against

resistant microbes. First- or second-generation oral antibiotics help prevent skin and soft tissue infections. There are 50% of MRSA strains also resist macrolides, clindamycin, and cephalosporins (A-I). Some *S. aureus* (e.g., MRSA) strains are born clindamycin-resistant. An accurate diagnosis requires a bacterial culture, and the efficacy of an antibiotic treatment depends on whether the disease-causing organism is resistant to the medications.

DECLARATION

Acknowledgments

We, thank you to the Suresh Gyan Vihar University, for their constant support and providing all facilities to complete this work.

Author contributions

Sen P, Gupta M and Khulbe P: Wrote and revised the first draft. Chauhan N: English editing. Ahire ED and Keservani RK: Proofreading and editing of final draft. All authors are agreed the final version and submitted the article.

Ethics approval

Not applicable.

Conflict of interest

Eknath D. Ahire and Raj K. Keservani are Editorial Board Members. The article was subject to the journal's standard procedures, with peer review handled independently of these members and their research groups.

REFERENCES

1. Lipsky BA, Moran GJ, Napolitano LM, Vo L, Nicholson S, Kim M. A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes. *BMC Infect Dis.* 2012;12:227.
2. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis.* 2014;59(2):e10-e52.
3. Sigmundsdottir H. Improving topical treatments for skin diseases. *Trends Pharmacol Sci.* 2010;31(6):239-245.
4. Jain S, Patel N, Shah MK, Khatri P, Vora N. Recent advances in lipid-based vesicles and particulate carriers for topical and transdermal application. *J Pharm Sci.* 2017;106(2):423-445.
5. Kwak YG, Choi SH, Kim T, et al. Clinical guidelines for the antibiotic treatment for community-acquired skin and soft tissue infection. *Infect Chemother.* 2017;49(4):301-325.
6. Ahire ED, Talele SG, Shah HS. Nanoparticles as a promising technology in microbial pharmaceuticals. In: Mahapatra DK, Talele SG, Haghi, eds. *Applied Pharmaceutical Science and Microbiology.* Apple Academic Press; 2020:133-158.
7. Reboli AC, Farrar WE. *Erysipelothrix rhusiopathiae*: an occupational pathogen. *Clin Microbiol Rev.* 1989;2(4):354-359.
8. Kontoyiannis DP, Sumoza D, Tarrand J, Bodey GP, Storey R, Raad II. Significance of aspergillia in patients with cancer: a 10-year study. *Clin Infect Dis.* 2000;31(1):188-189.
9. Walmsley S, Devi S, King S, Schneider R, Richardson S, Ford-Jones L.

- Invasive Aspergillus infections in a pediatric hospital: a ten-year review. *Pediatr Infect Dis J.* 1993;12(8):673-682.
10. Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. *Am Fam Physician.* 2014;90(4):229-235.
 11. Hall LM, Gorges HJ, van Driel M, Magin P, Francis N, Heal CF. International comparison of guidelines for management of impetigo: a systematic review. *Fam Pract.* 2022;39(1):150-158.
 12. Picard D, Klein A, Grigioni S, Joly P. Risk factors for abscess formation in patients with superficial cellulitis (erysipelas) of the leg. *Br J Dermatol.* 2013;168(4):859-863.
 13. Haribalakrishna A, Vaddi V, Goyal M, Mascarenhas D. Successful management of a cutaneous abscess caused by *Candida albicans* in a very low birth weight neonate. *J Clin Neonatol.* 2022;11(4):219.
 14. Iwata S, Koyama H, Murata Y. Efficacy and safety of daptomycin in Japanese pediatric participants with complicated skin and soft tissue infections or bacteremia caused by gram-positive cocci. *J Infect Chemother.* 2022;28(3):406-412.
 15. Foomani FH, Mirza S, Mukhida S, et al. Machine learning techniques to identify antibiotic resistance in patients diagnosed with various skin and soft tissue infections. 2022: arXiv: 2202.13496. Accessed August 26, 2022. <https://arxiv.org/abs/2202.13496>
 16. Ahire ED, Sharma N, Gupta PC, et al. Developing Formulations of Prebiotics and Probiotics. In: Kesharwani RK, Rao TJM, Keservani RK, eds. *Prebiotics and Probiotics in Disease Regulation and Management.* Scrivener Publishing; 2022:271-290.
 17. Mamo A, Szeto MD, Sivesind TE, Dellavalle RP. From the Cochrane Library: interventions for the prevention of recurrent erysipelas and cellulitis. *J Am Acad Dermatol.* 2022;87(5):e157-e158.
 18. Ditsios K, Chitas K, Christidis P, Charatsis K, Katsimentzas T, Papadopoulos P. Necrotizing fasciitis of the upper extremity - A review. *Orthop Rev (Pavia).* 2022;14(3):35320.
 19. Ahire ED, Surana KR, Sonawane VN, et al. Immunomodulation Impact of Curcumin and Its Derivative as a Natural Ingredient. In: Kesharwani RK, Keservani RK, Sharma AK. *Nutraceuticals and Functional Foods in Immunomodulators.* Springer; 2022:253-269.
 20. Wilcox M, Yan JL, Gonzalez PL, Dryden M, Stone GG, Kantecki M. Impact of underlying comorbidities on outcomes of patients treated with ceftaroline fosamil for complicated skin and soft tissue infections: pooled results from three phase III randomized clinical trials. *Infect Dis Ther.* 2022;11(1):217-230.
 21. Russo A, Treccarichi EM, Torti C. The role of Gram-negative bacteria in skin and soft tissue infections. *Curr Opin Infect Dis.* 2022;35(2):95-102.
 22. Van Tol AL, Tang B, Mackie ID. A case of *Streptococcus canis* bacteremia, osteomyelitis, sacroiliitis, myositis, and abscess. *BMC Infect Dis.* 2022;22(1):621.
 23. Hesse EM, Godfred-Cato S, Bower WA. Antitoxin use in the prevention and treatment of Anthrax disease: a systematic review. *Clin Infect Dis.* 2022;75(Suppl 3):S432-S440.
 24. Surana KR, Ahire ED, Sonawane VN, Talele SG. Biomolecular and molecular docking: a modern tool in drug discovery and virtual screening of natural products. In: Mahapatra DK, Aguilar CN, Haghi AK, eds. *Applied Pharmaceutical Practice and Nutraceuticals.* Apple Academic Press; 2021: 209-223.
 25. Kouki C, Masmoudi A, Kammoun N, et al. Erysipeloid cutaneous leishmaniasis: a study of 40 cases of an unusual variant. *Int J Dermatol.* 2022;61(11):1380-1384.
 26. Ahire ED, Sonawane VN, Surana K. Role of drug repurposing in current treatment strategies against covid-19; systemic review. *Pharm Reson.* 2020;COVID-19 Special issue:24-29.
 27. Iwata K, Takai Y, Kitada N, Morishita N, Kiyona H. Mandibular Nodule Caused by *Mycobacterium marinum* with False Positive Interferon- γ Release Assay. A Case Report. *Intern Med.* 2022. (Epub ahead of print)
 28. Hindy JR, Haddad SF, Kanj SS. New drugs for methicillin-resistant *Staphylococcus aureus* skin and soft tissue infections. *Curr Opin Infect Dis.* 2022;35(2):112-119.
 29. Surana KR, Ahire ED, Sonawane VN, Talele SG, Talele GS. Informatics and methods in nutrition design and development. In: Carvajal-Millan E, Yaser AZ, Haghi AK, eds. *Natural Food Products and Waste Recovery.* Apple Academic Press; 2021:33-49.
 30. Lee AH, Berlyand Y, Dutta S, et al. CT utilization in evaluation of skin and soft tissue extremity infections in the ED: retrospective cohort study. *Am J Emerg Med.* 2023;64:96-100.
 31. Deshmukh MD, Patil MP, Ahire ED, Gosavi SB. Shatdhautta Ghrita: A Promising agent in the development of herbal creams. *J Pharm Negat Result.* 2022;13(1):1332-1343.
 32. Pal M, Gutama KP. Glanders: A Potential Bioterrorism Weapon Disease. *Am J Infect Dis Microbiol.* 2022;10:98-101.
 33. Menu E, Kabtani J, Roubin J, Ranque S, L'Ollivier C. Pericardial effusion due to *Trichosporon japonicum*: a case report and review of the literature. *Pathogens.* 2022;11(5):598.
 34. Chan AA, Flores EA, Navarrete M, Phan Tran D, Lee DJ, Miller LG. The effect of systemic antibiotics for suppurative skin and soft tissue infections on the skin microbiome. *Open Forum Infect Dis.* 2022;9(5):ofac141.
 35. Surana KR, Ahire ED, Sonawane VN, Talele SG, Talele GS. Molecular modeling: novel techniques in food and nutrition development. In: Carvajal-Millan E, Yaser AZ, Haghi AK, eds. *Natural Food Products and Waste Recovery.* Apple Academic Press; 2021: 17-31.
 36. Wilcox M, Yan JL, Gonzalez PL, Dryden M, Stone GG, Kantecki M. Impact of underlying comorbidities on outcomes of patients treated with ceftaroline fosamil for complicated skin and soft tissue infections: pooled results from three phase III randomized clinical trials. *Infect Dis Ther.* 2022;11(1):217-230.
 37. Uchida E, Saito S, Morita D, et al. Skin and soft tissue infections in adolescent chronic myeloid leukemia under dasatinib treatment. *Pediatr Blood Cancer.* 2022;69(8):e29714.
 38. Pujalte GGA, Costa LMC, Clapp AD, Presutti RJ, Sluzevich JC. More than skin deep: dermatologic conditions in athletes. *Sports Health.* 2023;15(1):74-85.
 39. Kline BP, Jegathanan NA. Necrotizing soft tissue infections of the perineum. *Clin Colon Rectal Surg.* 2022;35(3):237-243.
 40. Huang Y, Sanz J, Rodríguez N, et al. Quantitative assessments of late radiation-induced skin and soft tissue toxicity and correlation with RTOG scales and biological equivalent dose in breast cancer. *Clin Transl Oncol.* 2022;24(5):836-845.
 41. Ioannou P, Chatzisytheon D, Maraki S, Samonis G, Kofteridis DP. Mixed skin and soft tissue infection caused by *Rhodotorula glutinis* and *Enterococcus faecalis* in a diabetic patient: a case report. *Maedica.* 2022;17(1):211-214.
 42. Pelletier J, Gottlieb M, Long B, Perkins JC Jr. Necrotizing soft tissue infections (NSTI): pearls and pitfalls for the emergency clinician. *J Emerg Med.* 2022;62(4):480-491.
 43. Rogers AD, El Khatib A. Surgical management of pressure-induced skin and soft tissue injuries. UpToDate. Accessed August 26, 2022. https://www.uptodate.com/contents/surgical-management-of-pressure-induced-skin-and-soft-tissue-injuries/print?search=pressure-ulcers-epidemiology-&source=search_result&selectedTitle=3~150&usage_type=default&display_rank=3
 44. Nurjadi D, Fleck R, Lindner A, et al. Import of community-associated, methicillin-resistant *Staphylococcus aureus* to Europe through skin and soft-tissue infection in intercontinental travellers, 2011-2016. *Clin Microbiol Infect.* 2019;25(6):739-746.
 45. Golan Y. Current treatment options for acute skin and skin-structure infections. *Clin Infect Dis.* 2019;68(Suppl 3):S206-S212.
 46. Tobudic S, Forstner C, Burgmann H, et al. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. *Infection.* 2019;47(6):1013-1020.
 47. Restrepo A, Clark NM, Infectious Diseases Community of Practice of the American Society of Transplantation. *Nocardia* infections in solid organ transplantation: guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation. *Clin Transplant.* 2019;33(9):e13509.